Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM

Van Oosteram AT, Dumez H, Desai J, Stroobants S, Van den Abbeele A, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD. Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.